The Remaking of America’s Health Agencies: Inside the 2026 CDC, FDA, NIH, and HHS Restructuring

Remaking America’s Health Infrastructure: Inside the 2026 Restructuring of HHS, CDC, FDA, and NIH

The Department of Health and Human Services—the $1.7 trillion agency responsible for everything from drug approvals to disease surveillance to biomedical research—is undergoing its most dramatic restructuring in decades. Under HHS Secretary Robert F. Kennedy Jr., the transformation has touched every corner of the federal health apparatus, reshaping how the United States approaches public health, regulatory science, and medical innovation.

As 2026 unfolds, the restructuring has created a landscape of competing forces: ambitious reform agendas from the executive branch, bipartisan congressional pushback on funding cuts, leadership vacancies at critical agencies, and eroding public trust in the institutions Americans once relied upon. Understanding these changes is essential for anyone who cares about the future of American healthcare.

RFK Jr.’s Vision: The “Make America Healthy Again” Transformation

When Robert F. Kennedy Jr. was confirmed as HHS Secretary, he brought with him an agenda that was both ambitious and controversial. Central to his platform was the “Make America Healthy Again” (MAHA) initiative—a sweeping effort to reorient federal health policy toward chronic disease prevention, food system reform, and what Kennedy has called a “holistic” approach to public health.

The HHS announced a formal transformation plan that included mass layoffs, consolidation of agency functions, and a pivot away from what Kennedy characterized as an overemphasis on pharmaceutical interventions. “We are fundamentally rethinking how this department serves the American people,” the HHS stated in its restructuring announcement.

According to tracking by BioPharma Dive, Kennedy’s plan involved dramatic reshaping of the department through “mass layoffs and consolidation” of key divisions. The scope of the restructuring caught many career officials and public health experts off guard, leading to significant turnover in experienced staff at agencies including the FDA, CDC, and NIH.

The Funding Rollercoaster: Slash, Then Restore

Perhaps the most telling chapter in the 2026 health agency saga has been the budget battle. In 2025, the Trump administration proposed significant cuts to health agency budgets. The CDC’s program level was targeted for a reduction of over $1.2 billion—cuts that would have affected immunization programs, disease surveillance, and public health preparedness.

Then came the reversal. In February 2026, Congress passed a bipartisan budget that fully funded the health agencies, effectively restoring many of the cuts proposed in 2025. As NPR reported, it was “a 180-turn from how funding for health agencies were slashed in 2025.” The episode illuminated a fundamental tension: while the executive branch pursued aggressive restructuring, Congress—including members of both parties—proved unwilling to accept deep cuts to core public health functions.

Yet the CDC’s FY 2026 Congressional Justification still reflected significant turbulence. The agency’s budget authority was proposed at $4.04 billion, down from $4.58 billion in FY 2025. The Prevention and Public Health Fund—a key source of funding for immunization and prevention programs—was zeroed out entirely in the President’s budget proposal, a cut of nearly $894 million.

Leadership in Limbo: The Vacancy Problem

As of spring 2026, multiple high-level positions across federal health agencies remained vacant or in flux—a situation that Axios described as giving the Trump administration an opportunity “to pivot from contentious vaccine policies to a more mainstream public health strategy.”

The CDC has been without a permanent director for extended periods. In April 2026, President Trump nominated Dr. Erica Schwartz—a former HHS deputy surgeon general—to lead the agency, but her confirmation faced an uncertain path in the Senate. The FDA saw the departure of Commissioner Marty Makary after a tenure marked by controversies that critics said demonstrated the politicization of the agency’s regulatory processes.

The surgeon general position also remained stalled, with Trump’s nominee lacking sufficient Republican votes for confirmation, according to Axios reporting from March 2026. These leadership gaps have created what one policy analyst called “decision-making paralysis” at critical moments, particularly as the agencies grapple with emerging health threats, drug approval backlogs, and ongoing pandemic preparedness challenges.

FDA: A New Playbook for Regulation

The FDA’s trajectory in 2026 has been characterized by what observers have called a “new playbook”—one marked by frequent media announcements but less traditional rulemaking. According to an Associated Press report, the agency under the Trump administration has shifted toward “lots of media announcements but not much rulemaking.”

This approach has had concrete consequences. One of the most notable was the FDA’s announcement that it would no longer routinely approve COVID-19 vaccine updates for healthy adults—a position published by FDA senior official Dr. Vinay Prasad in a medical journal rather than through the traditional regulatory process.

Yet the FDA has also moved forward with important regulatory modernization. In January 2026, the agency published updated guidance expanding the pathway for low-risk digital health devices and clinical decision support software. The Human Foods Program released its 2026 deliverables, focusing on enhanced food safety oversight, ingredient safety determinations, and expanded state-level inspection partnerships.

The dual nature of the FDA’s 2026—less traditional regulation alongside targeted modernization in specific areas—reflects the broader uncertainty surrounding the agency’s direction under evolving leadership.

Public Trust at a Crossroads

Perhaps the most troubling metric for America’s health agencies is the erosion of public confidence. A KFF poll released in 2026 found low trust among the American public that the FDA is making independent, non-political decisions. The CDC faces similar skepticism, with polling suggesting that partisan divides now shape how Americans view even basic public health guidance.

This trust deficit has real-world consequences. Vaccine uptake rates have declined for multiple preventable diseases. Measles outbreaks—once a rarity in the United States—have become more frequent. Public health messaging around everything from food safety recalls to infectious disease prevention now navigates a fractured information environment where trust in the messenger is as important as the message itself.

Scientific American, in its 2026 health outlook, identified “federal attacks on public health” and the “systematic dismantling of federal health agencies” as among the most consequential developments to watch. The publication noted that health experts had “sounded the alarm” on the weakening of the CDC, FDA, and NIH under the current administration.

The Clinical Research Impact

The restructuring has rippled beyond public health into the clinical research enterprise. The Association of Clinical Research Professionals reported that “frequent changes in FDA leadership as well as high turnover in experienced agency staff have increased anxiety levels among clinical research professionals.”

Sophia McLeod, Advocacy Advisor at the Association of Clinical Research Organizations, noted that competing priorities in AI regulation guidance, state-level legislation, and congressional debates over federal frameworks have created an uncertain environment for drug and device developers. “There are competing priorities in terms of guidance on artificial intelligence,” McLeod explained, pointing to draft FDA guidance, various state-level laws, and ongoing congressional working groups—all pulling in different directions.

This regulatory ambiguity affects the pace at which new treatments reach patients. When agencies are in flux, review timelines stretch, guidance documents are delayed, and companies face uncertainty about the standards against which their products will be evaluated.

What Comes Next

The restructuring of America’s health agencies is far from complete. With leadership vacancies still being filled, budgets contested between the executive and legislative branches, and fundamental questions about agency independence unresolved, 2026 represents a pivotal year.

Several developments will shape the trajectory in the months ahead:

• The confirmation process for the CDC director and surgeon general nominees will signal whether bipartisan support exists for the administration’s health leadership.
• The gap between proposed and congressionally-approved budgets will determine whether agencies have the resources to fulfill their mandates.
• The FDA’s evolving approach to drug approvals, vaccine policy, and digital health regulation will affect everything from pharmaceutical innovation to consumer access.
• And perhaps most importantly, whether public trust in these institutions can be rebuilt—or continues to erode—will shape the effectiveness of American public health for a generation.

For the millions of Americans who depend on these agencies for everything from food safety to drug approvals to pandemic preparedness, the stakes could not be higher. The restructuring of HHS, CDC, FDA, and NIH is not merely a Washington story—it is a healthcare story that touches every patient, every family, and every community in the country.